Perrigo (NYSE:PRGO – Get Free Report) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.250-2.550 for the period, compared to the consensus estimate of 2.110. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.1 billion.
Analyst Ratings Changes
A number of research analysts have recently weighed in on the company. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings cut Perrigo from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 29th. Argus raised Perrigo to a “hold” rating in a report on Wednesday, January 14th. Canaccord Genuity Group lowered their price target on Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Finally, Jefferies Financial Group reissued a “hold” rating on shares of Perrigo in a report on Thursday, February 26th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Perrigo currently has an average rating of “Hold” and an average target price of $19.33.
Read Our Latest Analysis on Perrigo
Perrigo Stock Performance
Perrigo (NYSE:PRGO – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.12. The firm had revenue of $841.80 million for the quarter, compared to the consensus estimate of $1.04 billion. Perrigo had a positive return on equity of 9.41% and a negative net margin of 33.51%.Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, equities analysts anticipate that Perrigo will post 2.12 earnings per share for the current fiscal year.
Perrigo Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Friday, May 29th will be given a $0.29 dividend. This represents a $1.16 annualized dividend and a yield of 10.0%. The ex-dividend date of this dividend is Friday, May 29th. Perrigo’s dividend payout ratio is -11.28%.
Institutional Investors Weigh In On Perrigo
Several hedge funds have recently made changes to their positions in PRGO. UMB Bank n.a. lifted its holdings in shares of Perrigo by 161.5% in the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after buying an additional 1,213 shares during the period. Geneos Wealth Management Inc. lifted its holdings in shares of Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after buying an additional 786 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of Perrigo in the 4th quarter worth $28,000. Kestra Investment Management LLC lifted its holdings in shares of Perrigo by 57.1% in the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after buying an additional 642 shares during the period. Finally, Danske Bank A S purchased a new stake in shares of Perrigo in the 3rd quarter worth $53,000. 95.91% of the stock is currently owned by hedge funds and other institutional investors.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.
Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.
Featured Articles
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.
